{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:10Z","timestamp":1786979890661,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00259-025-07084-7","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T05:01:50Z","timestamp":1737090110000},"page":"2118-2131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Value of [18F]AlF-NOTA-FAPI-04 PET\/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy"],"prefix":"10.1007","volume":"52","author":[{"given":"Yafei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-3982","authenticated-orcid":false,"given":"Xinhui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"7084_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493\u2013502. https:\/\/doi.org\/10.1038\/s41575-021-00457-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7084_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic Cancer: a review. JAMA. 2021;326:851\u201362. https:\/\/doi.org\/10.1001\/jama.2021.13027.","journal-title":"JAMA"},{"key":"7084_CR3","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1245\/s10434-016-5373-2","volume":"23","author":"SJ Rombouts","year":"2016","unstructured":"Rombouts SJ, Walma MS, Vogel JA, van Rijssen LB, Wilmink JW, Mohammad NH, et al. Systematic review of Resection Rates and clinical outcomes after FOLFIRINOX-Based treatment in patients with locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2016;23:4352\u201360. https:\/\/doi.org\/10.1245\/s10434-016-5373-2.","journal-title":"Ann Surg Oncol"},{"key":"7084_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1245\/s10434-022-12566-1","volume":"30","author":"N Ikenaga","year":"2023","unstructured":"Ikenaga N, Miyasaka Y, Ohtsuka T, Nakata K, Adachi T, Eguchi S, et al. A prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with arterial involvement. Ann Surg Oncol. 2023;30:193\u2013202. https:\/\/doi.org\/10.1245\/s10434-022-12566-1.","journal-title":"Ann Surg Oncol"},{"key":"7084_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","volume":"21","author":"TF Stoop","year":"2024","unstructured":"Stoop TF, Theijse RT, Seelen LWF, Groot Koerkamp B, van Eijck CHJ, Wolfgang CL, et al. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:101\u201324. https:\/\/doi.org\/10.1038\/s41575-023-00856-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7084_CR6","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1200\/JCO.2009.21.9022","volume":"27","author":"PA Philip","year":"2009","unstructured":"Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009;27:5660\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.21.9022.","journal-title":"J Clin Oncol"},{"key":"7084_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N, et al. Liquid biopsy response evaluation Criteria in Solid Tumors (LB-RECIST). Ann Oncol. 2024;35:267\u201375. https:\/\/doi.org\/10.1016\/j.annonc.2023.12.007.","journal-title":"Ann Oncol"},{"key":"7084_CR8","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1002\/cncr.26651","volume":"118","author":"D Chatterjee","year":"2012","unstructured":"Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118:3182\u201390. https:\/\/doi.org\/10.1002\/cncr.26651.","journal-title":"Cancer"},{"key":"7084_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/SLA.0000000000003442","volume":"273","author":"G Perri","year":"2021","unstructured":"Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, et al. Radiographic and Serologic Predictors of Pathologic Major Response to preoperative therapy for pancreatic Cancer. Ann Surg. 2021;273:806\u201313. https:\/\/doi.org\/10.1097\/SLA.0000000000003442.","journal-title":"Ann Surg"},{"key":"7084_CR10","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/annonc\/mdx495","volume":"28","author":"M Reni","year":"2017","unstructured":"Reni M, Zanon S, Balzano G, Nobile S, Pircher CC, Chiaravalli M, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786\u201392. https:\/\/doi.org\/10.1093\/annonc\/mdx495.","journal-title":"Ann Oncol"},{"key":"7084_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5858\/arpa.2011-0144-RA","volume":"136","author":"DJ Hartman","year":"2012","unstructured":"Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 2012;136:100\u20139. https:\/\/doi.org\/10.5858\/arpa.2011-0144-RA.","journal-title":"Arch Pathol Lab Med"},{"key":"7084_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamasurg.2022.5696","volume":"158","author":"AY Hammad","year":"2023","unstructured":"Hammad AY, Hodges JC, AlMasri S, Paniccia A, Lee KK, Bahary N, et al. Evaluation of Adjuvant Chemotherapy Survival outcomes among patients with surgically resected pancreatic carcinoma with node-negative Disease after Neoadjuvant Therapy. JAMA Surg. 2023;158:55\u201362. https:\/\/doi.org\/10.1001\/jamasurg.2022.5696.","journal-title":"JAMA Surg"},{"key":"7084_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2214\/AJR.16.16532","volume":"208","author":"S Sheikhbahaei","year":"2017","unstructured":"Sheikhbahaei S, Mena E, Yanamadala A, Reddy S, Solnes LB, Wachsmann J, et al. The value of FDG PET\/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer. AJR Am J Roentgenol. 2017;208:420\u201333. https:\/\/doi.org\/10.2214\/AJR.16.16532.","journal-title":"AJR Am J Roentgenol"},{"key":"7084_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ijrobp.2019.12.038","volume":"106","author":"AS Borggreve","year":"2020","unstructured":"Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, et al. Preoperative prediction of pathologic response to Neoadjuvant Chemoradiotherapy in patients with Esophageal Cancer using (18)F-FDG PET\/CT and DW-MRI: a prospective Multicenter Study. Int J Radiat Oncol Biol Phys. 2020;106:998\u20131009. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.12.038.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7084_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00330-019-06370-x","volume":"30","author":"L Tang","year":"2020","unstructured":"Tang L, Wang XJ, Baba H, Giganti F. Gastric cancer and image-derived quantitative parameters: part 2-a critical review of DCE-MRI and (18)F-FDG PET\/CT findings. Eur Radiol. 2020;30:247\u201360. https:\/\/doi.org\/10.1007\/s00330-019-06370-x.","journal-title":"Eur Radiol"},{"key":"7084_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ctrv.2019.06.002","volume":"77","author":"JM Zaucha","year":"2019","unstructured":"Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A. The role of PET\/CT in the modern treatment of Hodgkin lymphoma. Cancer Treat Rev. 2019;77:44\u201356. https:\/\/doi.org\/10.1016\/j.ctrv.2019.06.002.","journal-title":"Cancer Treat Rev"},{"key":"7084_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ijrobp.2006.12.039","volume":"68","author":"SL Breen","year":"2007","unstructured":"Breen SL, Publicover J, De Silva S, Pond G, Brock K, O\u2019Sullivan B, et al. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys. 2007;68:763\u201370. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.12.039.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7084_CR18","doi-asserted-by":"publisher","unstructured":"Tricarico P, Chardin D, Martin N, Contu S, Hugonnet F, Otto J, et al. Total metabolic tumor volume on (18)F-FDG PET\/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2023-007628.","DOI":"10.1136\/jitc-2023-007628"},{"key":"7084_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-022-01256-w","volume":"15","author":"WG Breen","year":"2022","unstructured":"Breen WG, Hathcock MA, Young JR, Kowalchuk RO, Bansal R, Khurana A, et al. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET\/CT. J Hematol Oncol. 2022;15:36. https:\/\/doi.org\/10.1186\/s13045-022-01256-w.","journal-title":"J Hematol Oncol"},{"key":"7084_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/BF03215860","volume":"25","author":"RK Kasperk","year":"2001","unstructured":"Kasperk RK, Riesener KP, Wilms K, Schumpelick V. Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon\u2019s view. World J Surg. 2001;25:1134\u20139. https:\/\/doi.org\/10.1007\/BF03215860.","journal-title":"World J Surg"},{"key":"7084_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrgastro.2013.42","volume":"10","author":"O Strobel","year":"2013","unstructured":"Strobel O, Buchler MW. Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol. 2013;10:203\u20135. https:\/\/doi.org\/10.1038\/nrgastro.2013.42.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7084_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210443.","journal-title":"J Nucl Med"},{"key":"7084_CR23","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-022-05758-0","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S, et al. [(18)F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET\/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49:2761\u201373. https:\/\/doi.org\/10.1007\/s00259-022-05758-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7084_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2967\/jnumed.123.266283","volume":"65","author":"X Li","year":"2024","unstructured":"Li X, Lu N, Lin L, Chen Y, Yang S, Wang H, et al. (18)F-FAPI-04 outperforms (18)F-FDG PET\/CT in clinical assessments of patients with pancreatic adenocarcinoma. J Nucl Med. 2024;65:206\u201312. https:\/\/doi.org\/10.2967\/jnumed.123.266283.","journal-title":"J Nucl Med"},{"key":"7084_CR25","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00259-021-05638-z","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Cheng K, Fu Z, Zheng J, Mu Z, Zhao C, et al. [(18)F]AlF-NOTA-FAPI-04 PET\/CT uptake in metastatic lesions on PET\/CT imaging might distinguish different pathological types of lung cancer. Eur J Nucl Med Mol Imaging. 2022;49:1671\u201381. https:\/\/doi.org\/10.1007\/s00259-021-05638-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7084_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld C, Ferrone CR, Katz MHG, Philip PA, Hong TS, Hackert T, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20:318\u201337. https:\/\/doi.org\/10.1038\/s41571-023-00746-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"7084_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/PAS.0000000000002013","volume":"47","author":"AJ Sohn","year":"2023","unstructured":"Sohn AJ, Taherian M, Katz MHG, Prakash LR, Chatterjee D, Wang H, et al. Integrated Pathologic score effectively stratifies patients with pancreatic ductal Adenocarcinoma who received Neoadjuvant Therapy and Pancreaticoduodenectomy. Am J Surg Pathol. 2023;47:421\u201330. https:\/\/doi.org\/10.1097\/PAS.0000000000002013.","journal-title":"Am J Surg Pathol"},{"key":"7084_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/modpathol.2017.87","volume":"31","author":"RK Pai","year":"2018","unstructured":"Pai RK, Pai RK. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy. Mod Pathol. 2018;31:4\u201323. https:\/\/doi.org\/10.1038\/modpathol.2017.87.","journal-title":"Mod Pathol"},{"key":"7084_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2016.01.043.","journal-title":"Cancer Lett"},{"key":"7084_CR30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","volume":"186","author":"Y Chhabra","year":"2023","unstructured":"Chhabra Y, Weeraratna AT. Fibroblasts in cancer: Unity in heterogeneity. Cell. 2023;186:1580\u2013609. https:\/\/doi.org\/10.1016\/j.cell.2023.03.016.","journal-title":"Cell"},{"key":"7084_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drup.2005.03.002","volume":"8","author":"T Kelly","year":"2005","unstructured":"Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat. 2005;8:51\u20138. https:\/\/doi.org\/10.1016\/j.drup.2005.03.002.","journal-title":"Drug Resist Updat"},{"key":"7084_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/RLU.0000000000004480","volume":"48","author":"A Kosmala","year":"2023","unstructured":"Kosmala A, Serfling SE, Schlotelburg W, Lindner T, Michalski K, Schirbel A, et al. Impact of 68 Ga-FAPI-04 PET\/CT on staging and therapeutic management in patients with Digestive System tumors. Clin Nucl Med. 2023;48:35\u201342. https:\/\/doi.org\/10.1097\/RLU.0000000000004480.","journal-title":"Clin Nucl Med"},{"key":"7084_CR33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.6004\/jnccn.2022.7041","volume":"20","author":"AM Abdelrahman","year":"2022","unstructured":"Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP, et al. FDG-PET predicts neoadjuvant therapy response and survival in Borderline Resectable\/Locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2022;20:1023\u2013e323. https:\/\/doi.org\/10.6004\/jnccn.2022.7041.","journal-title":"J Natl Compr Canc Netw"},{"key":"7084_CR34","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.ejso.2020.02.002","volume":"46","author":"E Mohamed","year":"2020","unstructured":"Mohamed E, Needham A, Psarelli E, Carroll M, Vinjamuri S, Sanghera B, et al. Prognostic value of (18)FDG PET\/CT volumetric parameters in the survival prediction of patients with pancreatic cancer. Eur J Surg Oncol. 2020;46:1532\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2020.02.002.","journal-title":"Eur J Surg Oncol"},{"key":"7084_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/bjs\/znab229","volume":"109","author":"W Lee","year":"2021","unstructured":"Lee W, Oh M, Kim JS, Park Y, Kwon JW, Jun E, et al. Metabolic activity by FDG-PET\/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Br J Surg. 2021;109:61\u201370. https:\/\/doi.org\/10.1093\/bjs\/znab229.","journal-title":"Br J Surg"},{"key":"7084_CR36","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11547-014-0473-1","volume":"120","author":"S Hu","year":"2015","unstructured":"Hu S, Zhang J, Zuo C, Cheng C, Liu Q, Sun G. (18)F-FDG-PET\/CT findings in pancreatic metastasis. Radiol Med. 2015;120:887\u201398. https:\/\/doi.org\/10.1007\/s11547-014-0473-1.","journal-title":"Radiol Med"},{"key":"7084_CR37","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.diii.2019.07.006","volume":"100","author":"M Wartski","year":"2019","unstructured":"Wartski M, Sauvanet A. 18F-FDG PET\/CT in pancreatic adenocarcinoma: a role at initial imaging staging? Diagn Interv Imaging. 2019;100:735\u201341. https:\/\/doi.org\/10.1016\/j.diii.2019.07.006.","journal-title":"Diagn Interv Imaging"},{"key":"7084_CR38","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1097\/JS9.0000000000001389","volume":"110","author":"W Lee","year":"2024","unstructured":"Lee W, Oh M, Kim JS, Sung M, Hong K, Kwak BJ, et al. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Int J Surg. 2024;110:4074\u201382. https:\/\/doi.org\/10.1097\/JS9.0000000000001389.","journal-title":"Int J Surg"},{"key":"7084_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/RLU.0000000000003561","volume":"46","author":"M Deng","year":"2021","unstructured":"Deng M, Chen Y, Cai L. Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in the imaging of pancreatic Cancer with Liver metastases. Clin Nucl Med. 2021;46:589\u201391. https:\/\/doi.org\/10.1097\/RLU.0000000000003561.","journal-title":"Clin Nucl Med"},{"key":"7084_CR40","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1007\/s00259-022-05729-5","volume":"49","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET\/MR and (18)F-FDG PET\/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:2877\u201388. https:\/\/doi.org\/10.1007\/s00259-022-05729-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7084_CR41","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1007\/s00330-023-09445-y","volume":"33","author":"Q Liu","year":"2023","unstructured":"Liu Q, Shi S, Liu S, Xu X, Hu S, Zhang J, et al. The added value of [(68)Ga]Ga-DOTA-FAPI-04 PET\/CT in pancreatic cancer: a comparison to [(18)F]F-FDG. Eur Radiol. 2023;33:5007\u201316. https:\/\/doi.org\/10.1007\/s00330-023-09445-y.","journal-title":"Eur Radiol"},{"key":"7084_CR42","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1007\/s00259-022-06100-4","volume":"50","author":"J Ding","year":"2023","unstructured":"Ding J, Qiu J, Hao Z, Huang H, Liu Q, Liu W, et al. Prognostic value of preoperative [(68) Ga]Ga-FAPI-04 PET\/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics. Eur J Nucl Med Mol Imaging. 2023;50:1780\u201391. https:\/\/doi.org\/10.1007\/s00259-022-06100-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7084_CR43","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s00259-021-05559-x","volume":"49","author":"NG Quigley","year":"2022","unstructured":"Quigley NG, Steiger K, Hoberuck S, Czech N, Zierke MA, Kossatz S, et al. PET\/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the Cancer integrin alphavbeta6 with Ga-68-Trivehexin. Eur J Nucl Med Mol Imaging. 2022;49:1136\u201347. https:\/\/doi.org\/10.1007\/s00259-021-05559-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7084_CR44","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.7150\/thno.100116","volume":"14","author":"SA Esfahani","year":"2024","unstructured":"Esfahani SA, Ma H, Krishna S, Shuvaev S, Sabbagh M, Deffler C, et al. Collagen type I PET\/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Theranostics. 2024;14:5745\u201361. https:\/\/doi.org\/10.7150\/thno.100116.","journal-title":"Theranostics"},{"key":"7084_CR45","doi-asserted-by":"publisher","first-page":"e220749","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306:e220749. https:\/\/doi.org\/10.1148\/radiol.220749.","journal-title":"Radiology"},{"key":"7084_CR46","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","volume":"49","author":"Y Liu","year":"2022","unstructured":"Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, et al. Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2022;49:871\u201380. https:\/\/doi.org\/10.1007\/s00259-021-05554-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7084_CR47","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijsu.2013.02.023","volume":"11","author":"B Nakata","year":"2013","unstructured":"Nakata B, Amano R, Kimura K, Hirakawa K. Comparison of prognosis between patients of pancreatic head cancer with and without obstructive jaundice at diagnosis. Int J Surg. 2013;11:344\u20139. https:\/\/doi.org\/10.1016\/j.ijsu.2013.02.023.","journal-title":"Int J Surg"},{"key":"7084_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1471-2288-12-78","volume":"12","author":"MW Fagerland","year":"2012","unstructured":"Fagerland MW. t-tests, non-parametric tests, and large studies\u2013a paradox of statistical practice? BMC Med Res Methodol. 2012;12:78. https:\/\/doi.org\/10.1186\/1471-2288-12-78.","journal-title":"BMC Med Res Methodol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07084-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:26:54Z","timestamp":1745303214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07084-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7084"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07084-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical study was approved by the institute\u2019s ethics committee of the First Affiliated Hospital, Zhejiang University School of Medicine (Clinical Trials.gov. ID NCT05884463). All recruited patients signed a written informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent has been obtained from the patients to publish this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential conflicts of interest of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}